Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Kindstar Globalgene Technology OCF Margin %?
Kindstar Globalgene TechnologyHKSE:09960 +3.09%69 OCF Margin % is 26.21% as of Dec. 2025, which is 251% above its 10-year median of 7.47. GuruFocus rates HKSE:09960 with a GF Score™ of 69/100 and a GF Value™ of HK$1.06 (Fairly Valued). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Kindstar Globalgene Technology ranks better than 57.35% on this metric.
The historical rank and industry rank for Kindstar Globalgene Technology's OCF Margin % or its related term are showing as below:
HKSE:09960'
s OCF Margin % Range Over the Past 10 Years
Min: -4.76 Med: 7.47 Max: 11.94
Current: 9.86
During the past 8 years, the highest OCF Margin % of Kindstar Globalgene Technology was 11.94%. The lowest was -4.76%. And the median was 7.47%.
HKSE:09960's OCF Margin % is ranked better than 57.35% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.55
vs HKSE:09960: 9.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09960 vs TMO, DHR, NTRA: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology (HKSE:09960) has a OCF Margin % of 26.21% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kindstar Globalgene Technology and its competitors. This is 251% above median its historical median of 7.47. According to the industry distribution chart, Kindstar Globalgene Technology ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 42.6%.
Is Kindstar Globalgene Technology's OCF Margin % too high?
Kindstar Globalgene Technology's current OCF Margin % of 26.21% is 251% above median its 10-year median of 7.47. The Medical Diagnostics & Research industry median OCF Margin % is 5.55. Kindstar Globalgene Technology's value of 26.21% is 372.3% above this industry median. Based on the distribution chart, Kindstar Globalgene Technology ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #87 out of 204 companies for OCF Margin %. This puts Kindstar Globalgene Technology in the upper half of its industry. The industry median OCF Margin % is 5.55. Kindstar Globalgene Technology's value of 26.21% is 372.3% above this benchmark. While the company's 10-year median is 7.47 vs. the industry median of 5.55, Kindstar Globalgene Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 5.55, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kindstar Globalgene Technology's current OCF Margin % of 26.21% is 372.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kindstar Globalgene Technology and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current OCF Margin % is 26.21%, which is 251% above median its own 10-year median of 7.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current OCF Margin % is 26.21%, which is 251% above median its 10-year median of 7.47 and 372.3% above the Medical Diagnostics & Research industry median of 5.55. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current OCF Margin % is 26.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
OCF Margin %: 26.21% (251% above median its 10-year median of 7.47)
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
Industry Position: 372.3% above the Medical Diagnostics & Research median (#87 of 204)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
